

Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results for the Nine Months Ended December 31, 2024 [Under Japanese GAAP]

February 5, 2025
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.

Code number: 4569

Web site: <https://www.kyorin-pharm.co.jp/>

Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer

Contact: Sakurou Banba, Director, Finance & Accounting

TEL (03) 6374-9704

Scheduled date to commence dividend payments: -

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: None

(Amounts rounded down to the nearest million yen)

1. Consolidated financial results for the nine months ended December 31, 2024 (from April 1, 2024 to December 31, 2024)

(1) Consolidated operating results (cumulative)

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended December 31, 2024	89,286	2.3	3,115	-35.1	3,753	-30.4	2,439	-41.2
December 31, 2023	87,267	8.1	4,803	—	5,391	—	4,149	—

(Note) Comprehensive income: For the nine months ended December 31, 2024: 2,361 million yen (-41.8%),
For the nine months ended December 31, 2023: 4,056 million yen (— %)

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
Nine months ended December 31, 2024	42.46		—	
December 31, 2023	72.32		—	

(Note) Beginning this fiscal year, the company changed accounting policies. The results of the nine months ended December 31, 2023 are presented after retroactive adjustment. The year-on-year changes are not provide presented, as retrospective adjustments have been made due to changes in accounting policies.

(2) Consolidated financial position

	Total assets		Net assets		Equity ratio	
	Million yen		Million yen		%	
As of December 31, 2024	190,492		130,073		68.3	
March 31, 2024	177,627		130,735		73.6	

(Note) Equity: For the nine months ended December 31, 2024: 130,073 million yen,
For the fiscal year ended March 31, 2024: 130,735 million yen

(Note) Beginning this fiscal year, the company changed accounting policies. The results for fiscal year ended March 31, 2024 are presented after retroactive adjustment.

2. Dividends

(Record date)	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2024	—	20.00	—	32.00	52.00
Fiscal year ended March 31, 2025	—	20.00	—		
Fiscal year ending March 31, 2025 (Forecast)				32.00	52.00

(Note) Revisions to the dividend forecast in the current quarter: None

3. Forecast of consolidated for the year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	123,400	3.2	6,500	4.3	6,900	1.1	5,000	-8.7	87.03

(Note) Revisions to the dividend forecast in the current quarter: None

(Note) The year-on-year change rate is presented based on a comparison with the retrospectively adjusted figures of the previous period, following retrospective adjustments due to changes in accounting policies

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): None

Newly included: None, Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other than (i) : Yes

(iii) Changes in accounting estimates : None

(iv) Restatements : None

(4) Number of shares issued (common stock)

(i) Number of issued shares at the end of the period (including treasury shares)

As of December 31, 2024: 64,607,936 shares,

Fiscal year ended March 31 2024: 64,607,936 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2024: 7,159,038 shares,

Fiscal year ended March 31 2024: 7,159,151 shares

(iii) Averaged number of shares of during the period

As December 31, 2024: 57,448,842 shares,

As of December 31, 2023: 57,369,574 shares

* This financial report is not subject to audit procedures by Certified Public Accountants or audit firm.

* Explanations about the appropriate use of the business forecasts and other noteworthy points.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

Supplementary Information will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.